Background: Statin therapy is highly successful for the treatment of hypercholesterolemia and prevention of cardiovascular disease. Side effects including muscle pain (myalgia), weakness and/or increased serum CK activity (myositis) often disrupt treatment, with no unifying hypothesis to explain them. We used genome-wide association to investigate whether genetic links to myalgia may be statin-specific. Methods: We genotyped 812 statin-treated patients with an array of 865,483 SNPs. There were 328 patients on atorvastatin, 119 on simvastatin; 154 on rosuvastatin, 213 on other statins. Myalgia index was scored as 1 for myalgia presence in 377 patients and 0 for no myalgia in 416. Results: The SNP rs7014327 of the ceroid lipofuscinosis, neuronal 8 (CLN8) gene was associated with myalgia at a significance of p < 2·10 -7 (R 2 = 5.2%) in patients receiving atorvastatin only. In all patients the SNP was unassociated (p < 10 -5 , R 2 = 2.6%). CLN8 encodes a protein implicated in Pompe's disease, whose hallmark is myopathy. Conclusion: We propose a new candidate for myalgia, CLN8, which has an effect only in atorvastatin patients. This drug dependent association supports the hypothesis of statin-specific pathways for statin myopathy. 
